MAbSilico

MAbSilico is a TechBio startup founded in 2017, headquartered in France, and operates in the Biotechnology and Health Care industries. The company's slogan, "The only TechBio providing computationally designed antibodies through AI with biological validations associated," encapsulates its core focus. MAbSilico specializes in AI-based solutions for antibody drug design and discovery, aiming to assist biotech and pharma companies in mitigating antibody discovery risks. MAbSilico's approach involves the use of 3D modeling, interaction simulation, and linear sequences analysis to swiftly provide computational antibody candidates, which are then characterized in silico and validated using cutting-edge biological technologies. These candidates are thoroughly assessed based on various parameters such as epitope, affinity, off-target risk, cross-species reactivity, and developability to ensure readiness for biological activity evaluation. The company harnesses NLP technologies to gather comprehensive information about antibodies and their targets from diverse databases, enabling competitive landscape analysis and assessment of the freedom to operate for the computationally designed antibody candidates.